<DOC>
	<DOCNO>NCT02558959</DOCNO>
	<brief_summary>This study design investigate effect second-line irinotecan capecitabine versus irinotecan alone gemcitabine cisplatin refractory advance biliary tract cancer patient .</brief_summary>
	<brief_title>Second-line Irinotecan Capecitabine Versus Irinotecan Gemcitabine Cisplatin Refractory Biliary Tract Cancer</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patients histologically confirm advanced biliary tract cancer experience progression firstline gemcitabine cisplatin Age 18 year older Measurable reference cancer site ( ) confirm compute tomography ( CT ) magnetic resonance imaging ( MRI ) Karnofsky performance status ( KPS ) least 70 % Adequate renal function , adequate hepatic function , adequate bone marrow function The presence severe concomitant disease could interrupt plan treatment Intractable pain Hypersensitivity study drug Serious cardiovascular disease If female , pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>